Three New Domestically Produced Corona Vaccines Debut at the International Trade and Services Fair When Foreign Media Reported on a Complicated Mentality | new pneumonia corona_Sina Finance_Sina.com

Original title: Three new domestically produced corona vaccines debuted at the International Trade and Service Fair, and foreign media reported a complicated mindset.

[Text / Observer.net Guo Han]Last weekend, three domestically made inactivated vaccines for novel coronavirus made their collective debut at the 2020 China International Trade in Services Fair, representing China’s “national team” of vaccines against the epidemic. world. Issue the answer sheet. Faced with this significant progress in vaccine research and development in China, some foreign media are unexpectedly bitter.

　　The new inactivated vaccine crowns at the China Biological booth during the 2020 International Trade in Services Conference. Image from: Beijing News

On September 5, the Beijing Institute of Biological Products, the Wuhan Institute of Biological Products, and Kexing Holding Biotechnology Co., Ltd. (Kexing) developed three inactivated vaccines for the new crown under Sinopharm China National Biotechnology Co., Ltd. , Debuted at the service fair booth, the specifications and instructions for each vaccine were presented in detail.

On-site staff revealed that these vaccines are currently in the third phase of international trials and are expected to be available later this year. The annual output of the two companies can reach 300 million. China Biotech revealed that the prices will be based on the principles of “public goods”, classified and affordable prices.Common peopleAffordable and quiet.

As a hope for people across the country and the world to return to normal social life, the collective emergence of the three domestic vaccines has attracted much attention from the domestic and foreign media. However, foreign media showed a complicated mindset when reporting. Some people questioned the slander and others believed that China seized the opportunity to “show off”, but there were also reports objectively acknowledging China’s progress in vaccine research and development.

The US media magazine “Fortune” admitted that Chinese vaccine research and development companies are in the “pole position” of the global competition for research and development, occupying 5 of the 9 research and development projects for vaccines. They are currently in the third phase.

The report mentioned that Kexing Chairman and CEO Yin Weidong first revealed at the exhibition that he, 90% of the company’s employees (about 3,000) and their family members have been vaccinated. Yin Weidong said this is to ensure that if the epidemic breaks out again, the development and production of Kexing’s vaccine will not be affected by preventive measures.

In the emergency use plan of the new corona virus vaccine officially launched in China on July 22, special populations such as medical personnel, epidemic prevention personnel, border inspection personnel, and personnel ensuring basic urban operations are object of emergency vaccination.

However, the “Fortune” magazine article “yin and yang strangely” implied that China’s practice of arranging emergency vaccination before the end of Phase III clinical trials is “non-traditional” and “may be problematic.” , and “challenges first.” limit”.

Indeed, Russian President Vladimir Putin announced on August 11 that the Russian Health Ministry had approved the world’s first new corona vaccine, passed all necessary tests, and had proven effective. But Russia’s omission of Phase III clinical trials has also caused controversy.

On August 27, Yang Hailun, Kexing’s senior director of Investor Relations, confessed to CNN that vaccine development is not a competition with your peers, but a race against the virus. “We want everyone (the company) to be successful so that there are enough vaccine supplies to protect people.”

On the other hand, the United States is so concerned about China’s current progress in vaccine research and development. The New York Times even forcibly defined it as “competition between spies”, discrediting China’s attempts to “steal” the results of the US investigation.

As for the collective “bright sword” of the China Vaccine Corps this time, some foreign media also kept the bitter grape mentality and thought it was “show off”.

Agence France-Presse described the vaccine as a “game changer” and wrote directly “China’s first show with the new coronavirus vaccine” in the title. The media claimed that China’s move was an attempt to “rewrite the narrative on the new corona epidemic,” highlighting its leadership and resilience in the face of an unprecedented threat to public health.

As of August, at least 6.7 billion doses of vaccines have reportedly been ordered worldwide. Chinese national leaders promised in May this year that the new domestically made corona vaccine will be used as a global public product once it is completed and put into use. The Global Times previously quoted Liu Jingzhen, party secretary and chairman of Sinopharm Group, to reveal that the protection rate of the two-shot vaccine is 100% and the price is less than 1,000 yuan.

Professor Michael Jinqi of the Washington University School of Public Health in St. Louis told the Politico website that China’s research and development projects take into account both inactivated and nucleic acid vaccines. Compared to the United States and Europe, the nucleic acid-only vaccine development pathway is more comprehensive and fault-tolerant. The rate is higher.

He believes that the United States “puts too many eggs in the same basket.” In the event that the nucleic acid vaccine program becomes invalid due to luck or biological evolution, the United States will regress to the dilemma that there is no vaccine available. “If it is interchangeable, I will choose the Chinese (project).”

However, some foreign media have objectively reported on China’s investment and progress in vaccine research and development. Spanish news agency EFE quoted China expert Julio Ríos on Aug. 27 as saying that providing the new coronavirus vaccine as a global public product will improve China’s status in the minds of many countries. Faced with the negative performance of developed countries, these countries will be deeply impressed by China’s active efforts. For China, it is very important to fully demonstrate its cooperative position to drastically contrast with the “exclusive position” of the United States.

According to a Reuters report, Kexing media representative Liu Peicheng revealed on Monday that in the first and second phase of trials involving 421 volunteers over the age of 60 in May this year, the company’s vaccine showed no effects. obvious secondary. Among the three groups of participants who were vaccinated with small, medium and high doses, 90% had an obvious immune response, which was slightly lower than the level among the youth.

The report acknowledges that the data shows that the Kexing vaccine appears to be safe, although the effect is slightly weaker in the elderly. In addition, the company’s vaccines are said to have a shelf life of up to 3 years, which favors distribution in areas that lack cold chain storage. Kexing is currently conducting the final phase of the third trial in Brazil and Indonesia.

Editor in Charge: He Zhongfu